Acridine

Acridine

SCHEMBL1551975

F.c1ccc2nc3ccccc3cc2c1

nearest known ligand 0.94

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.94
MAPT P10636 3/20 0.94
HPGD P15428 3/20 0.94
GLA P06280 2/20 0.94
ACHE P22303 1/20 0.94
HTR3A P46098 1/20 0.62
NQO2 P16083 2/20 0.60
KDM4E B2RXH2 3/20 0.54
GAA P10253 3/20 0.54
KMT2A Q03164 3/20 0.54
NPC1 O15118 2/20 0.54
POLB P06746 2/20 0.54
LMNA P02545 1/20 0.54
PTBP1 P26599 1/20 0.54
RAB9A P51151 1/20 0.54
RCE1 Q9Y256 1/20 0.54
TDP1 Q9NUW8 1/20 0.50
STAT3 P40763 1/20 0.50
MEN1 O00255 1/20 0.48
USP2 O75604 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acridine SCHEMBL8339 0.97 ALDH1A1 (1.00) ALDH1A1MAPTHPGDGLAACHE
Acridine SCHEMBL1772714 0.97 ALDH1A1 (1.00) ALDH1A1MAPTHPGDGLAACHE
Acridine SCHEMBL4972293 0.97 ALDH1A1 (1.00) ALDH1A1MAPTHPGDGLAACHE
Acridine SCHEMBL3045498 0.97 ALDH1A1 (1.00) ALDH1A1MAPTHPGDGLAACHE
Acridine SCHEMBL29352289 0.97 ALDH1A1 (1.00) ALDH1A1MAPTHPGDGLAACHE
Anthracene SCHEMBL9879830 0.94 MAPT (0.94) ALDH1A1MAPTHPGDGLAACHE
Acridine SCHEMBL2394207 0.94 ALDH1A1 (0.94) ALDH1A1MAPTHPGDGLAACHE
Acridine SCHEMBL641951 0.94 ALDH1A1 (0.94) ALDH1A1MAPTHPGDGLAACHE
Acridine SCHEMBL2401648 0.94 ALDH1A1 (0.94) ALDH1A1MAPTHPGDGLAACHE
Acridine SCHEMBL10801271 0.94 ALDH1A1 (0.94) ALDH1A1MAPTHPGDGLAACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2312943-A2 METHOD AND KIT FOR ASSESSING VIABLE CELLS Chemometec A/S (DK) 2011-04-27 EP claimed
CN-101903775-A The S100A12C compound (ERAC) of anti-EDTA ERAC AS 2010-12-01 CN claimed
EP-2210102-A2 EDTA RESISTANT S100A12 COMPLEXES (ERAC) Erac As (NO) 2010-07-28 EP claimed
WO-2010006615-A2 METHOD AND KIT FOR ASSESSING VIABLE CELLS CHEMOMETEC A/S (DK) 2010-01-21 WO claimed
WO-2009050277-A2 EDTA RESISTANT S100A12 COMPLEXES (ERAC) ERAC AS (NO) 2009-04-23 WO claimed
EP-2312943-B1 METHOD FOR ASSESSING VIABLE CELLS AND THE USE OF N-(7-DIMETHYLAMINO-4-METHYL-3-COUMARINYL)-MALEIMIDE (DACM) OR N-(9-ACRIDINYL)MALEIMIDE (NAM) FOR ASSESSMENT OF APOPTOSIS. CHEMOMETEC AS (DK) 2019-11-06 EP disclosed
US-20160131658-A1 METHOD AND KIT FOR ASSESSING VIABLE CELLS CHEMOMETEC AS (DK) 2016-05-12 US disclosed
US-9128097-B2 Method and kit for assessing viable cells CHEMOMETEC A/S (DK) 2015-09-08 US disclosed
EP-2312943-A2 METHOD AND KIT FOR ASSESSING VIABLE CELLS Chemometec A/S (DK) 2011-04-27 EP disclosed
WO-2010006615-A2 METHOD AND KIT FOR ASSESSING VIABLE CELLS CHEMOMETEC A/S (DK) 2010-01-21 WO disclosed